Subscribe free!

Find out why we're the #1 free penny stock alert newsletter


Sunesis Pharmaceuticals (SNSS) Stock rises in Tuesday’s Session

| |

Sunesis Pharmaceuticals (OTC: SNSS) stock closed Tuesday at $3.49, up 32.20 percent from its previous close of $2.64. The stock opened the session at $3.86 and touched its highest price point at $4.02. SNSS’s lowest price point for the session stood at $3.43. Its latest trading volume has been recorded at 8.85 million shares, in contrast to the average daily trading volume of 420K shares. The company’s market capitalization stands at $164.39 million. SNSS reported its latest Earnings per Share at -$0.78. The company has 47.10 million shares outstanding in the market and 62 percent of its share capital is owned by institutional investors. SNSS stock is currently trading below its short-term 20-days moving average price of $3.5. It is also trading above its long-term 50-days moving average price of $3.52. The company stock’s beta is 2.14.

SNSS has been rated a Buy by Equity Research firm Cantor Fitzgerald. The stock’s price target has been set at $8.00. SNSS stock was earlier priced at $6.00.

The company also made one time sample size increase to its Phase 3 Valor trial. The therapy is being tested for the treatment of acute myeloid leukemia. Daniel Swisher, CEO of the company said, “Importantly, we are pleased that we have committed funding that will allow us to implement this enrollment expansion and complete the pivotal trial in AML.” The one time increase consists of 225 new patients. With this increase, the total patients enrolled in the study are increased to 675.

SNSS is a biopharmaceutical company  engaged in the business of developing and marketing oncology therapies. The company has many drug candidates in the pipeline including Vosaroxin. SNSS is carrying out various studies such as REVEAL-1 and VALOR for testing the drugs. The company has licensing arrangement with Dainippon Sumitomo for developing and commercializing Vosaroxin. The company is also involved in the development of small molecular inhibitors. SNSS is collaborating with Biogen Idec Inc. for this purpose. The company’s former name is Mosaic Pharmaceuticals Inc.

Posted by on Wednesday, September 12th, 2012. Filed under Internet, Security. You can follow any responses to this entry through the RSS 2.0. You can leave a response or trackback to this entry

This newsletter is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. is a wholly-owned subsidiary of BlueWave Advisors.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Leave a Reply